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AnalgesiaAbstract A series of 8-(substituted)aryloxycaffeine were prepared from 8-bromocaffeine and
(substituted)phenols by modiﬁed Ullmann reaction. In vitro antibacterial activity, inhibitory activity
on topoisomerase II and pharmacological activities were evaluated for the synthesized 8-(substi-
tuted)aryloxycaffeine. Among the synthesized compounds, 8-(5-chloropyridin-3-yloxy)caffeine
(3k) showed strong inhibitory activity (MIC = 15.6 lg/mL) against the tested gram negative ()
bacteria Salmonella enteritidis. 8-(quinolin-8-yloxy)caffeine (3g) showed the strongest inhibitory
activity against topoisomerase II. And the compounds 8-(6-methylpyridin-2-yloxy)caffeine (3j)
and 8-(3-chloro-6-(triﬂuoromethyl)pyridin-2-yloxy)caffeine (3m) showed analgesic effect without
the central nervous system stimulation.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Caffeine (1) is a xanthine alkaloid found in the seeds, leaves
and fruit of some plants. Mainly, coffee beans, tea leaves,cocoa beans and kola nut are the most well known natural
sources of caffeine. Caffeine is most commonly consumed
worldwide by humans in infusion extracted from the seeds of
the coffee plant and the leaves. In addition, caffeine containing
soft drinks and energy drinks are also popular in the world.
Caffeine is a central nervous system (CNS) and metabolic
stimulant (Nehlig et al., 1992) and is used both recreationally
and medically to reduce physical fatigue and to restore alert-
ness when drowsiness occurs. It produces increased wakeful-
ness, faster and clearer ﬂow of thought, increased focus, and
better general body coordination (Bolton and Null, 1981). It
is an important class of adenosine receptor (AR) antagonists
(Daly, 2000; Franchetti et al., 1994; Huang et al., 2005;
Lobo et al., 1997; Mu¨ller and Stein, 1996; Strappaghettiloxycaf-
2 A.A. Kadi et al.et al., 2001), phosphodiesterase (PDE) inhibitor, DNA
intercalating agents and inhibitors of acetyl- and butyryl-
cholinesterase (Kramer et al., 1977; Mu¨ller et al., 2002;
Rodrı´guez-Franco et al., 2005; Shamim et al., 1989; Shimada
et al., 1991; Wells et al., 1981).
Studies on caffeine derivatives have shown that 8-(substi-
tuted)caffeine (e.g. 3-(3-hydroxypropyl)-7-methyl-1-propar-
gyl-8-[(m-methoxy)styryl]xanthine, MSX-2) is a selective A2A
adenosine receptor antagonists (Muller, 2000; Mu¨ller et al.,
1998), A1 receptor (Corsano et al., 1995) in which 8-(di-substi-
tuted amino)caffeine belongs to a pharmacologically important
subclass (Scammells et al., 1994) and acetylcholinesterase
(AChE) inhibitor (Rodrı´guez-Franco et al., 2005). 8-
Cyclohexylcaffeine, which in binding studies has shown to be
150 times more potent at adenosine A2 receptor in platelets
than in A1 receptor in cortical membranes (Shamim et al.,
1989). In the past two decades, studies on 8-methoxycaffeine
have shown that it possesses a topoisomerase II inhibitory
activity (Gellert, 1981; Matsuura and Saito, 1969; Russo
et al., 1991, 1997; Tornaletti et al., 1992, 1989; Walther et al.,
1989), while caffeine and 8-chlorocaffeine are less potent.
Recently, it was reported that (Russo et al., 1997) 8-chlorocaf-
feine antagonized the A1 adenosine receptor at the rat phrenic-
hemidiaphragm. 8-akyloxycaffeine is also reported as
phosphodiesterase (PDE) inhibitor (Walther et al., 1989), and
it causes DNA unwinding (Tornaletti et al., 1989), where caf-
feine unwinding potency is less than 8-methoxycaffeine
(Tornaletti et al., 1992). It has been found that, 8-alkoxycaf-
feine is very sensitive to photosensitized oxygenation in
MeOH, therefore it causes oxidative damage to DNA and
amino acids, but in case of caffeine it easily suffers photosensi-
tized oxygenation in alkaline media (Gellert, 1981) (Chart 1).
Despite its potency, very fewmethods for synthesizing 8-aky-
loxycaffeine derivatives have been reported during the last two
decades, especially for 8-aryloxycaffeine, not much work has
been done so far. Anyway, in 1934, Ralph C. Huston (Huston
and Allen, 1934) synthesized 8-substituted (-O-phenyl)caffeine
by using Fisher’s method (Fischer, 1884), which was later
repeated by W. Wiglicerus (Wislicenus and Ko¨rber, 1902), and
H. Biltz (Wislicenus and Ko¨rber, 1902), consisted simply in
heating 8-halocaffeine in methyl or ethyl alcohol solution con-
taining an excess of sodium or potassium alcoholate.
Recently, Masakazu Sono et al. (Sono et al., 1994) used electro-
chemical oxidation of caffeine using KF as electrode in
1.5 V in 2.5 h in MeOH and obtained 43% of 8-methoxycaf-
feine. Very recently, Hans-Zimmer et al. (Biltz and Bergius,
1918) used sodium metal in THF by reﬂuxing 10 h with
moderate yields. However, none of the above methods has
been widely applied for the preparation of 8-(substi-
tuted)aryloxycaffeine. Since 8-methoxycaffeine is more
potent than caffeine and it has one characteristic ether bond
in position 8 of caffeine, therefore, 8-(substituted)aryloxycaf-
feine might be the good candidate for the future develop-
ment of biological active agents. As a part our study in
developing methodology as well as synthesizing natural/un-
natural biological active molecule and evaluation of their
biological activity, in this article, we report thirteen novel
8-(substituted)aryloxycaffeine (3a–m) via Ullmann reaction
and evaluated their antibacterial activity against 12 gram
positive/negative bacterial strains, topoisomerase II inhibi-
tory activity and pharmacological actions.Please cite this article in press as: Kadi, A.A. et al., Synthesis, biological evaluation
feine. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.2. Results and discussion
2.1. Chemistry
As a part of our interest (Mohideen et al., 2013; Rahman et al.,
2009; Sono et al., 1994; Zimmer et al., 1999) on searching new
biological active molecules, a series of 8-(substituted)-aryloxy-
caffeine (3a–m) were synthesized from 8-bromocaffeine (2).
Initially, 8-bromocaffeine (2) was prepared using bromine
and sodium acetate in acetic acid at 60 C from commercially
available 1. Modiﬁed Ullmann reaction (Ullmann, 1904)
condition was applied for the synthesis of 8-(substituted)ary-
loxycaffeine (3a–m) and obtained good to excellent yields
(75–98%) (Scheme 1).
2.2. Biology
2.2.1. In vitro antibacterial activity
In vitro antimicrobial activities of synthesized compounds (3a–
m) against the microorganisms employed and their activity
potentials were qualitatively and quantitatively assessed by
the presence or absence of inhibition zones. All the experi-
ments were performed in triplicates and the results were given
as the arithmetic mean of these triplicates. As shown in
Table 1, 3a–m exhibited a potent inhibitory effect against
Staphylococcus aureus (KCTC 1916), Salmonella enteritidis
(KCTC 12021), Salmonella typhimurium (KCTC 2515), and
Bacillus subtilis ATCC 6633 with the diameter of inhibition
zones ranging from 10 to 16 mm whereas Streptomycin
(10 lg/disc) showed the diameter of inhibition zones range
14 mm. It should be noted that, 3a–m shows inhibitory effect
against all the bacteria tested at 150 lg/disc and the data are
summarized in Table 1.
2.2.2. Minimum inhibitory concentration (MIC)
Table 2 shows the MIC values for the compounds 3a–m
against the tested gram () bacteria such as S. enteritidis
(KCTC 12021), and gram positive (+) bacteria B. subtilis
ATCC 6633, which were found in the range of 15.62–125
(lg/mL). Among the synthesized compounds, 3k showed
strong inhibitory activity with the value of 15.6 lg/mL against
the tested gram negative () bacteria S. enteritidis. In addition,
compounds 3b, 3i and 3l also show the excellent inhibitory
activity with the value of 31.2 lg/mL against the tested gram
negative () bacteria S. enteritidis and gram positive (+) bac-
teria B. subtilis.2.2.3. DNA topoisomerase II inhibitory activity
Topo II inhibitory activity of the compounds 3a–m was mea-
sured by assessing the relaxation of supercoiled pBR 322
plasmid DNA employing the method previously described
(Fukuda et al., 1996). As shown in Table 3, among the
caffeine derivatives, 1,3,7-trimethyl-8-(quinolin-8-yloxy)-1H-
purine-2,6(3H,7H)-dione (3g) was the most active inhibitor
showing 28.42% and 48.92% inhibition comparable to
42.82% and 66.87% of etoposide at the concentrations of
20 lM and 100 lM, respectively. Not only that, but also all
of the compounds (3a–m) showed moderate inhibitory activity
against Topo II (Table 3).and Structure Activity Relationships (SARs) study of 8-(substituted)aryloxycaf-
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Chart 1 Structure of some potent 8-substituted caffeine derivatives.
Scheme 1 Synthesis of 8-(substituted)aryloxycaffeine (3a–m) from caffeine (1) via 8-bromocaffeine.
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Table 1 Antibacterial activity of 3a–m against tested bacterial strains by disc diffusion method (Murray et al., 1995).
Microorganism Compoundsa Antibioticsb
3a 3b 3c 3d 3e 3f 3g 3h 3i 3j 3k 3l 3m SM TC
S. aureus (KCTC 1916) 12 14 13 12 11 12 11 13 10 13 13 12 12 14 18
S. typhimurium (KCTC 2515) 13 14 12 14 14 13 12 13 10 12 10 12 13 14 18
S. enteritidis (KCTC 12021) 15 16 16 13 13 14 12 13 14 12 11 12 13 14 19
P. aeruginosa (KCTC 2004) 13 14 11 11 13 12 13 11 13 11 11 10 13 19 20
E. coli 0157:H7 (ATCC 43888) 12 14 13 12 12 13 12 14 12 11 12 11 13 15 19
E. aerogenes (KCTC 2190) 11 13 11 11 12 13 10 12 11 12 09 11 12 15 20
B. subtilis (ATCC 6633) 13 13 14 13 13 15 14 13 10 12 11 12 13 14 18
E. coli (ACTC 8739) 12 14 13 12 09 14 13 10 09 11 12 13 12 15 19
E. coli 0157 (Human) 10 13 12 14 12 15 11 09 10 10 08 10 12 14 20
L. monocytogenes (ACTC 19166) 10 13 12 13 10 12 10 12 10 16 10 12 10 14 21
S. aureus (ATCC 6538) 09 13 12 12 11 13 09 10 12 12 09 11 11 14 21
a Inhibition zone in millimetre around the discs impregnated with samples (150 lg/disc).
b SM: Streptomycin (10 lg/disc); TC: Tetracycline (10 lg/disc).
Table 2 MIC of 3a–m against tested bacterial strains by microdilution method (Ullmann and Sponagel, 1905).
Microorganism MIC (in lg/mL)
3a 3b 3c 3d 3e 3f 3g 3h 3i 3j 3k 3l 3m SM TC
S. enteritidis (KCTC 12021) 62.5 31.2 62.5 125 62.5 62.5 62.5 31.2 31.2 62.5 15.6 31.2 62.5 15.6 15.6
B. subtilis (ATCC 6633) 125 31.2 62.5 62.5 125 125 31.2 62.5 31.2 125 31.2 31.2 31.2 15.6 15.6
Table 3 Inhibitory activity of 3a–m against topoisomerase IIa.
Compound Inhibitory activity (%) Compound Inhibitory activity (%)
20 lM 100 lM 20 lM 100 lM
3a 10.23 17.22 3h 18.32 24.22
3b 10.56 16.63 3i 20.22 32.22
3c 14.32 24.45 3j 17.46 23.64
3d 12.54 18.37 3k 16.54 23.22
3e 18.21 29.32 3l 18.43 25.45
3f 16.22 26.54 3m 18.25 27.38
3g 28.42 48.92 Etoposide 42.82 66.87
a Topoisomerase II data were taken from our earlier published communication (Rahman and Yurngdong, 2011) for clariﬁcation.
Table 4 Motor activity on mice.
Compound Percentage change in locomotion
40 mg/kg 80 mg/kg
3a ›5 ›17
3e ﬂ28.5 ﬂ71.7
3f ﬂ9 ﬂ23
3h ›7.3 ›18.3
3j ﬂ19.2 ﬂ27.3
3b–d, 3g, 3i, 3k–m No eﬀect
Table 5 Effect of the compounds on the general behaviour in
mice.
Compound Doses
in mg/kg
Changes in behaviour
(during 2 h observation)
3a 100 Minor tremors
3a 200 Tremors and convulsions
3e 100 Severe sedation
3e 200 Severe sedation
3h 100 Minor tremors
3h 200 Tremors and convulsions
3j 100 No clear changes
3j 200 Calmness and sedation
3k 200 Micturition and defecation
3m 100 No clear changes
3m 200 Calmness, micturition and defecation
others 200 No eﬀect
4 A.A. Kadi et al.It has been found from the Topo II inhibitory evaluation
data that, substitution in any positions with phenyl or pyridyl
did not affect on inhibitory activity. Almost similar results
were obtained from all the compounds. Only the compoundPlease cite this article in press as: Kadi, A.A. et al., Synthesis, biological evaluation and Structure Activity Relationships (SARs) study of 8-(substituted)aryloxycaf-
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SARs study of 8-(substituted)aryloxycaffeine 5having quinolin substitution (3g) gave different inhibitory
activity than the others. Therefore, we can conclude that, main
skeleton of caffeine plays an important role for the synthesized
8-(substituted)-aryloxycaffeine and substituent with quinolin
moiety increases the inhibitory activity.
2.2.4. Pharmacology
2.2.4.1. Effect of the compounds on motor activity in mice. The
locomotion count for 10 min. per group of mice (N= 4) was
435 ± 7 counts. Table 4 shows the percentage change in the
count following the treatment of the animals with the differentTable 6 Pharmacological action of compounds 3a–m.
Substituent (compound) Activities Subs
3a
Increase in central nervous system
stimulation
OHC
3b
Loss of central activity
OHC
3c
Loss of central activity
O2N
3d
Loss of central nervous system activity
C
OCH3
OHC
3e
Central nervous system depression
C
OCH3
H3COC
3f
Loss of central nervous system
stimulation. Decrease in central nervous
system activity
F
N
3g
Loss of central nervous system activity
Please cite this article in press as: Kadi, A.A. et al., Synthesis, biological evaluation
feine. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.compounds. While, we injected 3a locomotion percentage was
increase 5% at 40 mg/kg dosage and increasing of dosage up to
80 mg/kg, locomotion also was increased 17%. Similarly,
injection of compound 3h also affected and increased the loco-
motion percentage. On the other hand, compounds 3e, 3f and
3j decreased the locomotion percentage very much. However,
we could not get any effect while we injected compounds 3b–
d, 3g, 3i or 3k–m.
2.2.4.2. Effect of the compounds on the general behaviour at
doses of 100/200 mg/kg (i.p). The results for the effect of thetituent (compound) Activities
N
3h
Increase in central nervous system stimulation
N
Cl
3i
Loss of central nervous system activity
N
3j
Loss of central nervous system activity
N
l
3k
Micturition and defection
N
l
3l 
Loss of central nervous system activity
N
3C
Cl
3m
Calmness, Sedation and Analgesia,
and Structure Activity Relationships (SARs) study of 8-(substituted)aryloxycaf-
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6 A.A. Kadi et al.compounds on the general behaviour on albino mice are
shown in Table 5. Less shaking (tremor) was observed after
injection of 100 mg/kg of 3a/3h but it was increasing depend-
ing on increasing of doses. No clear changes was observed with
100 mg/kg doses for 3j/3m but increasing of doses with
200 mg/kg for 3j became calmness and sedation was observed.
In case of 3 m (200 mg/kg), calmness then micturition ﬁnally
defection was observed. Interestingly, for compound 3e with
low or high doses severe sedation was observed.
2.2.4.3. Effect of the compounds on thermal pain. In mice trea-
ted with caffeine, the reaction time (before treatment) was 6 s.
This was increased to 13.5 s, 30 min. after treatment an
increase of 125%. In the mice treated with compound 3j, the
initial reaction time was 5.6 s. This was increased to 11.2 s
30 min. after treatment an increase of pain threshold by
100%. In the mice treated with compound 3m, the reaction
time was increased from 6.1 s to 12.3 s, an increase of
101.6%. There was no signiﬁcant change in the reaction time
in the animals treated with other compounds.
2.2.5. Structure Activity Relationship studies (SARs)
Modiﬁcation of the caffeine at 8-position by different sub-
stituents produced variations in the pharmacological action
of the basic molecule (caffeine). Detailed activities of synthe-
sized caffeine derivative are summarized in Table 6.
Themost interesting ﬁnding is that, substitution of 6-methyl-
pyridin-2-yloxy group at position 8 of caffeine namely, 1,3,7-tri-
methyl-8-(6-methylpyridin-2-yloxy)-1H-purine-2,6(3H,7H)-dione
(3j) and substitution of 3-chloro-6-(triﬂuoromethyl)pyridin-2-
yloxy group namely 8-(3-chloro-6-(triﬂuoromethyl)pyridin-2-
yloxy)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione (3m)
abolished the central nervous system activity of caffeine and left
the analgesic effect. Further modiﬁcation of these structures
may provide potent analgesics.
3. Conclusion
In conclusion, caffeine derivatives 3a–m were synthesized in
good to excellent yields. Their antimicrobial, topoisomerase
II Inhibitory and pharmacological activities have been eval-
uated. Compound 3k showed strong inhibitory activity
(MIC = 15.6 lg/mL) against the tested gram negative () bac-
teria S. enteritidis; 3g showed the strongest inhibitory activity
against topoisomerase II comparable to Etoposide; and the
compounds 3j and 3m showed the analgesic effect of caffeine
without any central stimulation.
4. Experimental
4.1. Chemistry
Melting points were determined using a Fisher-Jones melting
point apparatus and were not corrected. NMR spectra were
obtained using a Bruker-250 spectrometer 250 MHz for 1H
NMR and 62.5 MHz for 13C NMR and are reported as parts
per million (ppm) from the internal standard TMS. Chemicals
and solvents were commercial reagent grade and used without
further puriﬁcation. Electrospray ionization (ESI) massPlease cite this article in press as: Kadi, A.A. et al., Synthesis, biological evaluation
feine. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.spectrometry (MS) experiments were performed on a LCQ
advantage-trap mass spectrometer (Thermo Finnigan, San
Jose, CA, USA).
4.1.1. Preparation of 8-bromo-1,3,7-trimethyl-1H-purine-
2,6(3H,7H)-dione (2)
A solution of bromine (3.5 g, 1.1 equiv.) in acetic acid (35 mL)
was added dropwise to a solution of caffeine (1, 1.94 g,
10 mmol), sodium acetate (2.2 g, 1.1 equiv.) in acetic acid
(50 mL) over 30 min at room temperature. Themixture was stir-
red for 1 h and the solid formation was collected by ﬁltration,
washedwith cold acetic acid, dried over vacuum, obtainedwhite
powder (92%),mp. 207 C (lit (Vollmann andMu¨ller, 2002)mp,
206 C).
4.1.2. General procedure for the preparation of 8-substituted-
aryl caffeine ether (3a–m)
A mixture of 8-bromo-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-
dione (2,100 mg, 0.036 mmol), (substituted) arenols (1
equiv.), anhydrous K2CO3 (1 equiv.) in 10 mL of dry
DMF was heated at 100–110 C for 2–3 h under N2 atmo-
sphere. Upon cooling the reaction mixture at room tempera-
ture, water was added, resulting reaction mixture was kept at
4 C. The solid formation was ﬁltered and washed with cold
n-hexane to obtain crystalline solid which was pure enough
for analysis.
4.1.3. 1,3,7-trimethyl-8-phenoxy-1H-purine-2,6(3H,7H)-dione
(3a)
White solid (70%): mp 142–143 C [lit. (Huston and Allen,
1934) mp: 140–143 C]. Unreported spectral data are as fol-
lows: 1H NMR (CDCl3, 250 MHz) d 7.41 (t, J= 8.1 Hz,
2H), 7.25 (m, 3H), 3.86 (s, 3H), 3.44 (s, 3H), 3.39 (s, 3H).
13C NMR (CDCl3, 62.5 MHz) d 154.92, 153.41, 153.33,
151.62, 145.82, 129.75, 125.64, 119.36, 103.77, 30.41, 29.88,
27.81. MS (ESI) Calcd. for C14H14N4O3 [M+H]
+ 287.3.
Found 287.3.4.1.4. 3-(1,3,7-trimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-
8-yloxy)benzaldehyde (3b)
White solid (87%). mp = 164–65 C, 1H NMR (CDCl3,
250 MHz): d 10.00 (s, 1H, ACHO), 7.81 (s, 1H), 7.76 (m,
1H), 7.58 (m, 2H), 3.87 (s, 3H), 3.41 (s, 3H), 3.37 (s, 3H).
13C NMR (CDCl3, 62.5 MHz): d 190.90, 154.86, 153.80,
152.75, 154.50, 145.57, 137.93, 130.51, 127.43, 125.50, 119.49,
103.90, 30.46, 29.86, 27.81. MS (ESI) Calcd. for C15H14N4O4
[M+ H]+ 315.3. Found 315.3.4.1.5. 4-(1,3,7-trimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-
8-yloxy)benzaldehyde (3c)
White solid (87%). mp = 167–68 C, 1H NMR (CDCl3,
250 MHz): d 9.99 (s, 1H, ACHO), 7.94 (dm, J= 8.6 Hz,
2H), 7.48 (dm, J= 8.6 Hz, 2H), 3.87 (s, 3H), 3.43 (s, 3H),
3.38 (s, 3H). 13C NMR (CDCl3, 62.5 MHz): d 190.54,
157.65, 154.89, 152.03, 151.50, 145.51, 133.61, 131.63, 119.59,
103.96, 30.56, 29.89, 27.84. MS (ESI) Calcd. for C14H14N4O3
[M+ H]+ 315.3. Found 315.3.and Structure Activity Relationships (SARs) study of 8-(substituted)aryloxycaf-
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SARs study of 8-(substituted)aryloxycaffeine 74.1.6. 1,3,7-trimethyl-8-(4-nitrophenoxy)-1H-purine-
2,6(3H,7H)-dione (3d)
White solid (65%). mp = 207 C, 1H NMR (CDCl3,
250 MHz): d 8.30 (dm, J= 9.1 Hz, 2H), 7.52 (dm,
J= 9.1 Hz, 2H), 3.88 (s, 3H), 3.44 (s, 3H), 3.38 (s, 3H). 13C
NMR (CDCl3, 62.5 MHz): d 157.52, 154.86, 151.54, 151.45,
145.36, 144.88, 125.68, 119.73, 104.03, 30.61, 29.87, 27.86.
MS (ESI) Calcd. for C14H13N5O5 [M+H]
+ 332.2. Found
332.2.
4.1.7. 3-methoxy-4-(1,3,7-trimethyl-2,6-dioxo-2,3,6,7-
tetrahydro-1H-purin-8-yloxy)benzaldehyde (3e)
White solid (86%). mp = 185 C, 1H NMR (CDCl3,
250 MHz): d 9.95 (s, 1H, ACHO), 7.51–7.49 (m, 3H), 3.88
(s, 3H), 3.85 (s, 3H), 3.38 (s, 3H), 3.36 (s, 3H). 13C NMR
(CDCl3, 62.5 MHz): d 190.84, 154.94, 153.37, 151.56, 151.36,
146.87, 145.77, 134.93, 124.90, 121.91, 111.21, 103.90, 56.23,
30.52, 29.85, 27.80. MS (ESI) Calcd. for C16H16N4O5
[M+ H]+ 345.3. Found 345.3.
4.1.8. 8-(4-acetyl-2-methoxyphenoxy)-1,3,7-trimethyl-1H-
purine-2,6(3H,7H)-dione (3f)
White solid (91%). mp = 218 C, 1H NMR (CDCl3,
250 MHz): d 7.59 (s, 1H, H30), 7.57 (dd, 1H, J= 8.1,
1.8 Hz), 7.35 (d, J= 8.1 Hz, 1H), 3.86 (s, 3H), 3.81 (s, 3H),
3.34 (s, 3H), 3.34 (s, 3H), 2.59 (s, 3H). 13C NMR (CDCl3,
62.5 MHz): d 196.75, 154.88, 153.56, 151.53, 150.77, 145.82,
145.77, 135.67, 122.06, 121.36, 111.82, 103.81, 56.13, 30.45,
29.80, 27.74, 26.50. MS (ESI) Calcd. for C17H18N4O5
[M+ H]+ 359.2. Found 359.2.
4.1.9. 1,3,7-trimethyl-8-(quinolin-8-yloxy)-1H-purine-
2,6(3H,7H)-dione (3g)
White solid (95%). mp = 184 C, 1H NMR (CDCl3,
250 MHz): d 8.79 (dd, 1H, J= 4.3, 1.4 Hz, H20), 8.18 (dd,
1H, J= 8.4, 1.3 Hz, H40), 7.74 (dd, 1H, J= 8.0, 0.8 Hz,
H50), 7.64 (dd, 1H, J= 7.5, 0.8 Hz, H70), 7.54 (t, 1H,
J= 8.0 Hz), 7.42 (dd, 1H, J= 8.0, 4.3 Hz, H30), 4.01 (s,
3H), 3.38 (s, 3H), 3.27 (s, 3H). 13C NMR (CDCl3,
62.5 MHz): d 155.03, 154.99, 151.63, 150.50, 149.47, 145.95,
140.50, 136.01, 129.73, 126.24, 125.78, 121.94, 119.70, 103.82,
30.78, 29.80, 27.77. MS (ESI) Calcd. for C17H15N5O3
[M+ H]+ 338.3. Found 338.3.
4.1.10. ,3,7-trimethyl-8-(pyridin-2-yloxy)-1H-purine-
2,6(3H,7H)-dione (3h)
White solid (86%). mp = 287 C, 1H NMR (CDCl3,
250 MHz): d 7.47 (dt, 1H, J= 8.0, 6.8, 2.0 Hz, H50), 7.35
(dd, 1H, J= 6.9, 1.6 Hz, H60), 6.63 (d, 1H, J= 9.5 Hz,
H30), 6.33 (t, 1H, J= 6.7 Hz, H40), 3.83 (s, 3H), 3.54 (s,
3H), 3.41 (s, 3H). 13C NMR (CDCl3, 62.5 MHz): d 161.17,
155.24, 151.41, 146.37, 143.90, 141.48, 136.41, 121.85, 107.83,
107.14, 32.86, 29.83 and 28.06. MS (ESI) Calcd. for
C13H13N5O3 [M+ H]
+ 288.2. Found 288.2.
4.1.11. 8-(2-chloropyridin-3-yloxy)-1,3,7-trimethyl-1H-purine-
2,6(3H,7H)-dione (3i)
Pink solid (92%). mp = 174–75 C, 1H NMR (CDCl3,
250 MHz): d 8.29 (d, 1H, J= 3.8 Hz, H60), 7.89 (d, 1H,
J= 7.8 Hz, H, H40), 7.34 (dd, 1H, J= 7.8, 4.8 Hz, H50),Please cite this article in press as: Kadi, A.A. et al., Synthesis, biological evaluation
feine. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.3.89 (s, 3H), 3.35 (s, 3H), 3.34 (s, 3H). 13C NMR (CDCl3,
62.5 MHz): d 154.81, 152.27, 151.40, 146.42, 145.74, 145.36,
143.07, 130.40, 123.43, 104.04, 30.51, 29.78, 27.26. (ESI)
Calcd. for C13H12ClN5O3 [M+ H]
+ 322.3. Found 322.3.
4.1.12. 1,3,7-trimethyl-8-(6-methylpyridin-2-yloxy)-1H-purine-
2,6(3H,7H)-dione (3j)
White solid (80%). mp = 165–66 C, 1H NMR (CDCl3,
250 MHz): d 7.67 (t, 1H, J= 7.8 Hz, 1H), 7.01 (d,
J= 8.2 Hz, 1H), 6.98 (d, J= 8.6 Hz, 1H), 3.80 (s, 3H), 3.48
(s, 3H), 3.40 (s, 3H), 2.42 (s, 3H). 13C NMR (CDCl3,
62.5 MHz): d 159.73, 157.84 (C02), 155.08, 151.59, 145.76,
140.32, 120.56, 108.74, 104.53, 30.87, 29.86, 27.83 and 23.97.
(ESI) Calcd. for C14H15N5O3 [M+H]
+ 302.3. Found 302.3.
4.1.13. 8-(5-chloropyridin-3-yloxy)-1,3,7-trimethyl-1H-purine-
2,6(3H,7H)-dione (3k)
Pink solid (98%). mp = 193–94 C, 1H NMR (CDCl3,
250 MHz): d 8.56 (d, 1H, J= 2.5 Hz, H20), 8.46 (d, 1H,
J= 2.0 Hz, H60), 7.81 (t, 1H, J= 2.2 Hz, H40), 3.86 (s, 3H),
3.42 (s, 3H), 3.36 (s, 3H). 13C NMR (CDCl3, 62.5 MHz): d
154.83, 152.03, 151.41, 149.51, 145.77, 145.27, 139.65, 131.90,
127.23, 103.98, 30.51, 29.86, 27.82. (ESI) Calcd. for
C13H12ClN5O3 [M+ H]
+ 322.2. Found 322.2.
4.1.14. 8-(6-chloropyridin-2-yloxy)-1,3,7-trimethyl-1H-purine-
2,6(3H,7H)-dione (3l)
Pink solid (94%). mp = 169–70 C, 1H NMR (CDCl3,
250 MHz): d 7.77 (t, 1H, J= 8.0 Hz, 1H), 7.22 (d,
J= 8.0 Hz, 1H), 7.16 (d, J= 8.1 Hz, 1H), 3.83 (s, 3H), 3.48
(s, 3H), 3.40 (s, 3H). 13C NMR (CDCl3, 62.5 MHz): d
159.47, 155.10, 151.57, 150.60, 149.38, 145.63, 142.28, 121.58,
110.45, 104.73, 30.94, 29.88 and 27.89. (ESI) Calcd. for
C13H12ClN5O3 [M+ H]
+ 322.2. Found 322.2.
4.1.15. 8-(3-chloro-6-(triﬂuoromethyl)pyridin-2-yloxy)-1,3,
7-trimethyl-1H-purine-2,6(3H,7H)-dione (3m)
Dark-yellow solid (75%). mp = 288–89 C, 1H NMR (CDCl3,
250 MHz): d 7.77 (s, 2H, H40 and H50), 3.86 (s, 3H), 3.54 (s,
3H), 3.41 (s, 3H). 13C NMR (CDCl3, 62.5 MHz): 156.77,
155.17, 151.28, 146.22, 142.02, 134.80 (3JC–F = 6 Hz),
134.40, 128.60, 122.02 (1JC–F = 250 Hz), 111.26 (
2JC–
F = 36 Hz), 108.24, 33.23, 28.88 and 28.1d (ESI) Calcd. for
C14H11ClF3N5O3 [M+ H]
+ 390.2. Found 390.2.
4.2. Biology
4.2.1. Microorganisms
The following microorganisms obtained from the American
Type Culture Collection (ATCC), were used in this study:
Listeria monocytogenes ATCC 19166, B. subtilis ATCC 6633,
S. aureus (ATCC 6538), Escherichia coli ATCC 8739 and
E. coli O157:H7 ATCC 43888. Food contaminating Bacillus
cereus SCK 11 stain was obtained from College of
Veterinary Medicine, Konkuk University, Seoul, Republic of
Korea. Other pathogens such as S. aureus (KCTC 1916), S.
enteritidis (KCTC 12021), S. typhimurium (KCTC 2515),
Enterobacter aerogenes KCTC 2190 and Pseudomonas aerugi-
nosa (KCTC 2004) were obtained from the Korean
Collection for Type Cultures (KCTC). Active cultures forand Structure Activity Relationships (SARs) study of 8-(substituted)aryloxycaf-
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cells from stock cultures to ﬂasks and inoculated in Luria–
Bertani (LB) broth medium (1.0% tryptone, 0.5% yeast
extract, 1.0% NaCl, solidiﬁed with 1.5% agar when required)
at 37 C for 24 h. Cultures of each bacterial strains were main-
tained on LB agar medium at 4 C.
4.2.2. Antibacterial activity assay
The compounds (3a–m) were dissolved in ethanol to a ﬁnal con-
centration of 40 mg/mL and sterilized by ﬁltration through
0.45 lm Millipore ﬁlters. The antibacterial test was then carried
out by agar disc diffusion method (Murray et al., 1995) using
100 lL of standardized inoculum suspension containing
107 CFU/mL of bacteria. To prepare standardized inoculum,
bacteria were grown overnight in LB broth that was maintained
at 37 C with constant agitation until the density matched the
turbidity of a 0.5McFarland standard. Tube dilutionwith sterile
saline was carried out to obtain inocula of 107 CFU/mL. Then
sterile ﬁlter paper discs (6 mm diameter) were impregnated
with 10 lL of diluted compounds (3a–m) corresponding to
150 lg/disc separately, using capillary micro-pipette and placed
on the inoculated LB agar. Negative controls were prepared by
soaking the disc with ethanol only. Standard reference antibi-
otics, streptomycin and tetracycline (10 lg/disc, each from
Sigma–Aldrich Co., St Louis, MO), were used as positive
controls for the tested bacteria. The plates were incubated at
37 C for 24 h. Antibacterial activity was evaluated by measur-
ing the diameter of the zones of inhibition against the tested bac-
teria. Each assay in this experiment was replicated three times.
4.2.3. Minimum inhibitory concentration (MIC)
Minimum inhibitory concentration (MIC) of the compounds
(3a–m) was tested by twofold serial dilution method
(Ullmann and Sponagel, 1905). The compounds 3a–m were
ﬁrst dissolved in ethanol, and incorporated into LB broth med-
ium to obtain a concentration of 2000 lg/mL and serially
diluted to achieve 1000, 500, 250 125, 62.5, 31.25 and
15.62 lg/mL. The ﬁnal concentration of ethanol in the culture
medium was maintained at 0.1% (v/v). A 10 lL standardized
suspension of each tested organism (107 CFU/mL approxi-
mately) was transferred to each tube. The control tubes
containing only bacterial suspension were incubated at 37 C
for 24 h. The lowest concentration of the test samples, which
did not show any growth of tested organism after macroscopic
evaluation, was determined as the MIC.
4.2.4. DNA relaxation assay of Topo II
The mixture of 100 ng of supercoiled pBR322 plasmid DNA
and 0.2 units of human DNA Topo IIa (Amersham, USA)
was incubated without and with the prepared compounds
in the assay buffer (10 mM Tris–HCl (pH 7.9) containing
50 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 1 mM ATP,
and 15 lg/mL bovine serum albumin) for 30 min at 37 C.
The reaction in a ﬁnal volume of 10 lL was terminated by
the addition of 3 lL of 7 mM EDTA. Reaction products
are analysed on a 1% agarose gel at 25 V for 4 h with a run-
ning buffer of TAE. Gels were stained for 30 min in an aque-
ous solution of ethidium bromide (0.5 lg/mL). DNA bands
were visualized by transillumination with UV light and
supercoiled DNA was quantitated using AlphaImagerTM
(Alpha Innotech Corporation).Please cite this article in press as: Kadi, A.A. et al., Synthesis, biological evaluation
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4.2.5.1. Animals used. Male Swiss albino mice (25 ± 2 g body
weight) were used in this study. The animals were provided by
the experimental animals care centre, College of Pharmacy,
King Saud University, Riyadh, Kingdom Saudi Arabia. The
animals were housed in cages under controlled environmental
conditions comprising a temperature of 22 ± 2 C, 12 h
light/ dark cycle and a relative humidity of 50 ± 5%. The
animals are allowed free access to pulverized standard rodents’
pellets diet and tap water. The experimental protocol followed
in the under mentioned experiments was approved by the local
Ethical committee.
4.2.5.2. Motor activity: effect of the compounds on motor
activity in mice. The motor activity (locomotion) was measured
in mice groups (N= 4) (weight was 25 g each) using Apex
Activity Meter (Bagneux, France). Initially, each group of
mice was placed inside the cage of the activity meter and the
locomotion count was recorded for 10 min. The animals were
then injected with the test drug in doses of 40 or 80 mg/kg
intraperitoneally (1 or 2 mg/mouse). Then the animals were
replaced in the same cage of the activity meter and the locomo-
tion count was recorded for 10 min. The percentage change in
the locomotion count was then calculated.
4.2.5.3. Behaviour study: effect of the compounds on the general
behaviour at doses of 100/200 mg/kg (i.p). Albino mice (body
weight 20 g) were injected with the test compounds 100 and
200 mg/kg (i.p) and they were continuously observed for 2 h
for any changes in behaviour and effect on different body
systems.4.2.5.4. Thermal pain: effect of the compounds on thermal pain.
Pain was induced in Albino mice (body weight 25 g) using the
hot plate method (57 C) using Columbus Analgesia meter hot
plate model 39D (Columbus, Ohio, USA). Initially mice were
placed individually on the hot plate and the pain reaction time
(in seconds) was recorded. The reaction is deﬁned as lifting of
the forelimbs and licking or ﬂowing on them. Then each com-
pound or caffeine was administered (i.p) at 180 mg/kg (i.p).
Thirty minutes later the animals were tested for the reaction
time on the hot plate.References
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